Immunology startup Dualitas announced a $65 million Series A funding round to advance its bispecific antibody platform targeting two receptors on the same immune cell. Led by investors including Eli Lilly and Chugai Pharmaceutical, this financing will accelerate discovery of next-generation treatments for autoimmune and inflammatory diseases. The company leverages proximity biology to enhance immune modulation beyond monoclonal antibody capabilities, positioning itself as a notable innovator in the immunotherapy landscape.